Genmab accused by AbbVie of misappropriating trade secrets related to ADCs, vows to defend

From GlobeNewswire: 2025-03-21 23:29:00

AbbVie Inc. files a complaint against Genmab in the U.S. District Court for alleged misappropriation of trade secrets related to ADC development. Genmab refutes the allegations and plans to vigorously defend itself. The lawsuit involves the use of disaccharides to improve drug-linkers in ADCs, specifically in connection with rinatabart sesutecan (Rina-S™). Genmab acquired ProfoundBio, the company behind Rina-S, in May 2024. AbbVie is seeking damages and injunctive relief, but Genmab is committed to its clinical development plans for Rina-S and its collaboration with AbbVie for epcoritamab remains unaffected.



Read more at GlobeNewswire: Genmab to Vigorously Defend Alleged Claims of Trade Secret